Search Results

Yposkesi launches LentiSure™, Lentiviral (LV) Vector production platform optimized for higher yields

Evry-Courcouronnes (near Paris), France, April 5, 2023 – Yposkesi, SK pharmteco’s clinical and commercial viral vector manufacturing arm for cell and gene therapies, today announces the launch of LentiSure™,

April 27, 2023

·

4 min read

Business

Servier appoints Yposkesi for lentiviral vector GMP-manufacturing in CAR-T cell development technology

Service agreement gives Servier access to Yposkesi’s robust production capacity

June 5, 2019

·

4 min read

Business

CDMO Yposkesi appoints new Director of Viral Vector Manufacturing Operations

With 15 years’ bioproduction and cell & gene therapy expertise, Morad El Gueddari will take charge of Yposkesi’s industrial-scale viral vector manufacturing

April 24, 2019

·

2 min read

Business

Axovant and Yposkesi sign strategic gene therapy development and manufacturing partnership

Partnership secures access to reserved cGMP capacity and resources at Yposkesi for manufacturing to support the global development and commercialization of Axovant’s gene therapy programs

June 20, 2019

·

6 min read

Business

Yposkesi appoints Dr. Fraser Wright as senior advisor

With extensive experience in gene therapy vector manufacturing, Dr. Wright, scientific co-founder and former CTO of Spark Therapeutics, will support Yposkesi’s innovation in viral vector design, production and characterization

July 13, 2018

·

4 min read

Press Releases

SK pharmteco Unites Leading Brands to Create Global Powerhouse in CDMO Services

December 11, 2024

·

2 min read

Business

Yposkesi enters into agreement in principle for strategic partnership with Axovant to expand Axovant’s gene therapy manufacturing capacity

In the framework of a preferred partnership, Yposkesi plans to grant Axovant access to dedicated cGMP capacity and manufacturing resources to further support the global development and commercialization of Axovant’s AAV-based gene therapy programs

November 30, 2018

·

3 min read

Yposkesi’s viral vectors used in gene therapy-based clinical trial

EuroFanColen researchers published in Nature Medicine first clinical results for Fanconi anemia patients

September 9, 2019

·

2 min read

Yposkesi’s clinical batches of G1XCGD lentiviral vector used in rare immune system disease study

International research team published initial clinical trial results in Nature Medicine of nine X-Linked Chronic Granulomatous Disease (CGD) patients

February 2, 2020

·

3 min read

Business

Yposkesi Has Been Selected by Orchard Therapeutics to Produce Lentiviral Gene Therapy Vectors For Clinical Trials

As part of this partnership, Yposkesi will produce lentiviral vector batches to meet Orchard’s needs for clinical trials in primary immune deficiencies including X-linked chronic granulomatous disease.

December 18, 2017

·

3 min read